Racura Presents CPACS Data at GCOS 2026
Released
Released
Announcement PDF
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1
ASXAnnouncement
Racura Presents CPACS Phase 1 RC220
and Doxorubicin Data at the 2026
Global Cardio-Oncology Summit
§ Poster presented at Global Cardio-Oncology Summit 2026 entitled, “Cardioprotection & Anti-
cancer Synergy (CPACS) – A Phase 1 Study of RC220 in Combination with Doxorubicin – Trial in
Progress”
§ Presentation provides an update on the ongoing CPACS Phase 1 trial of RC220 with doxorubicin in
patients with advanced solid tumours
7 October 2026
Racura Oncology Ltd (“Racura” or the “Company”) is pleased to announce that it presented at the Global
Cardio-Oncology Summit 2026 (Williamsburg, Virginia) on 7 October 2026. The poster presentation
provides a clinical update on the Company’s ongoing Cardioprotection & Anticancer Synergy (CPACS)
Phase 1 study of RC220 in combination with doxorubicin in patients with advanced solid tumours.
Racura Oncology CEO and Managing Director, Dr Daniel Tillett, commented: “Presenting our CPACS clinical
study at the Global Cardio-Oncology Summit highlights the growing interest in RC220’s potential to address
cardiotoxicity, one of the key limitations of anthracycline-based cancer therapy, while also improving
anticancer treatments. The CPACS study is evaluating if RC220 can be safely combined with doxorubicin to
enhance anticancer activity and reduce cardiac injury. We appreciate the opportunity to update the
international cardio-oncology community on the progress of this important trial.”
A copy of the poster presentation is attached to this release.
Signi!cance of Anthracycline Cardiotoxicity
Anthracyclines remain central to many anticancer treatment regimens, but their clinical use is limited by
irreversible cardiotoxicity. RC220 is a proprietary formulation developed by Racura of (E,E)-bisantrene, a
clinically validated small molecule anticancer agent recently shown to act through G-quadruplex DNA and
RNA binding, leading to potent silencing of c-MYC oncogene expression in preclinical cancer models.
RC220 in combination with doxorubicin has shown improved anticancer activity in human and murine
tumour models and reduced anthracycline cardiotoxicity in human cardiomyocytes and multiple animal
cardiac models.
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 2
CPACS Trial
The CPACS study is a multicentre, open-label, two-part Phase 1 trial in adult patients with advanced solid
tumours, with enrolment ongoing in Australia, Hong Kong and South Korea. Part 1 is a Bayesian Optimal
Interval (BOIN)-guided dose-escalation study of IV RC220 administered in combination with 60 mg/m²
doxorubicin, preceded by monotherapy safety lead-in cycles of each agent.
The primary objective is to assess the safety and tolerability of the combination, with secondary objectives
including maximum tolerated combined dose, pharmacokinetics, anti-tumour efficacy and exploratory
cardioprotection biomarkers.
Following interim review, Part 2 will further evaluate safety, tolerability, preliminary anticancer activity and
protection of cardiac function after anthracycline exposure.
– ENDS –
•
The
trial
is
enrolling
at
sites
in
Australia,
Hong
Kong
and
South
Korea.
•
Cohort
1
Dose
Level
1
(RC220
40
mg/m²)
safety
cleared
by
SRC
escalated
based
on
BOIN
rule
•
Cohort
2
Dose
Level
2
(RC220
80
mg/m²)
is
enrolling
•
Safety
Review
Committee
oversight
continues
Racura
Oncology
Ltd.
L36,
1
Macquarie
Place,
Sydney
NSW
2000,
Australia
•
info@racuraoncology.com
•
feroz.ahmad@racuraoncology.com
•
www.racuraoncology.com
ClinicalTrials.gov:
NCT06815575
•
Poster
presented
at:
2026
Global
Cardio-Oncology
Summit,
Virginia,
USA
Patient
Demographics
&
Safety*
Pharmacokinetics
Cohort
Age
Sex
Disease
Type
Prior
Therapy
Treatment
Acute
AE
Status
Patient
1
1
87
M
Metastatic
Prostate
7
Lines
systemic/
3x
radiotherapy
Monotherapy:
well
tolerated
Combination:
Cycle
1
well
tolerated
No
Withdrawn
after
Cycle
1
due
to
frailty.
Patient
2
1
74
M
Metastatic
Prostate
7
Lines
systemic
Monotherapy:
well
tolerated
Combination:
Completed
5
cycles
No
EOT
due
to
PD.
Ongoing
in
study
follow
up
Patient
3
2
42
F
Metastatic
breast
(ER+/PR+/
HER2-)
5
Lines
systemic
Monotherapy:
well
tolerated
Combination:
Completed
2
cycles
No
EOT
due
to
PD.
Ongoing
in
study
follow
up
0
8
16
24
32
40
48
0.1
1
10
100
1000
Nominal
Time
(h)
Mean
Plasma
Concentration
(ng/ml)
Cohort
1
RC220
(40mg/m
2
)
+
Dox
(60mg/m
2
)
Cohort
1
RC220
(40mg/m
2
)
(E,E)-bisantrene
0
8
16
24
32
4
10
100
1000
10000
Norminal
Time
(h)
Mean
Plasma
Concentration
(ng/ml)
Doxorubicin
Cohort
1
RC220
(40mg/m
RESULTS
Abbreviations:
CTRCD,
cancer
therapy-related
cardiac
dysfunction;
DOX,
doxorubicin;
DL,
dose
level;
FUP,
follow
up;
LVEF,
left
ventricular
ejection
fraction;
MTCD,
maximum
tolerated
combined
dose;
PDx,
pharmacodynamic;
GLS,
global
longitudinal
strain,
cMRI,
cardiac
MRI;
EoS,
End
of
study;
LTS,
Long-Term
Safety;
D,
dose
CONCLUSION
•
Part
1
dose
escalation
is
ongoing
using
a
BOIN
design;
Cohort
1
has
completed
the
DLT
evaluation
period
with
no
DLTs
observed
and
no
unexpected
safety
signals
identified
to
date.
•
Early
(E,E)-bisantrene
displayed
a
biphasic
PK
profile
consistent
with
previous
observations,
with
no
apparent
influence
of
doxorubicin
on
(E,E)-bisantrene
PK;
dose
escalation
is
ongoing
toward
the
MTCD.
•
Safety
Review
Committee
concluded
that
the
available
safety
and
tolerability
data
supported
escalation
to
Dose
Level
2
–
RC220
80mg/m
2
.
•
Part
2
will
expand
at
the
MTCD
in
anthracycline-naïve
patients
to
evaluate
cardioprotection
using
complementary
functional,
imaging
and
biomarker
measures
(VO₂peak,
GLS/cMRI,
LVEF/CTRCD
and
PDx
surrogate),
and
continue
to
evaluate
antitumour
activity.
(E,E)-bisantrene
PK
following
i.v.
administration
in
the
Lead
Cycle
(RC220
only)
and
Cycle
1
(RC220
+
Dox)
SAFETY
SUMMARY
Cohort
1
(RC220
40
mg/m
2
)
•
Treatment-related
TEAEs
were
clinically
manageable;
diarrhoea
most
frequently
reported;
Most
events
resolved
or
resolving
at
data
cut-off
•
Grade
3
TEAEs:
diarrhoea,
fatigue,
hypotension,
decreased
platelet
count,
neutropenia;
no
Grade
4
or
5
TEAEs
were
reported.
•
One
Grade
3
diarrhoea
SAE
was
reported
as
a
SUSAR
during
combination
treatment,
considered
possibly
related
to
RC220
and
doxorubicin
in
the
presence
of
potential
confounding
factors;
the
event
resolved
with
medical
management.
Safety
Review
Committee
(SRC)
Assessment
•
No
DLTs
were
observed
during
the
protocol-defined
first-cycle
DLT
evaluation
period
at
CP2
40
mg/m²
+
doxorubicin
60
mg/m²
•
The
SRC
supported
escalation
to
Dose
Level
2
(RC220
80
mg/m²)
*Data
cut-off
date
30/06/2026
BACKGROUND
•
Anthracyclines
remain
essential
to
many
anticancer
protocols,
but
their
clinical
use
is
limited
by
irreversible
cardiotoxicity.
•
RC220
is
a
proprietary
formulation
of
(E,E)-bisantrene,
a
clinically
proven
small
molecule
anticancer
agent
recently
discovered
to
function
via
G-quadruplex
DNA
and
RNA
binding
that
results
in
silencing
of
MYC
gene
expression
and
MYC-driven
growth
pathways.
•
Preclinical
studies
have
shown
RC220
combined
with
doxorubicin
improves
anticancer
activity
in
tumour
models,
while
also
reducing
anthracycline
cardiotoxicity
in
human
cardiomyocytes,
and
murine
and
canine
cardiac
models.
Primary
(Part
1
&
2):
•
Evaluate
the
safety
and
tolerability
of
RC220
alone
and
in
combination
with
doxorubicin.
•
Incidence
of
dose-limiting
toxicities
(DLTs)
in
the
first
combination
cycle.
•
Treatment-emergent
adverse
events
(TEAEs)
and
serious
adverse
events
(SAEs),
per
NCI
CTCAE
v5.0.
KEY
Secondary
•
MTCD:
determine
the
maximum
tolerated
combination
dose
of
RC220
+
doxorubicin
(60
mg/m²)
-
Part
1
•
Antitumour
activity:
BOR,
DOR
and
PFS
per
RECIST
v1.1
-
Part
1&
2
•
Cardiac
safety:
RC220
+
doxorubicin
at
MTCD
(biomarkers,
ECG/Echo
including
GLS,
cardiac
MRI)
-
Part
2
•
Cardiorespiratory
fitness:
VO₂peak
(volume
of
peak
oxygen
uptake)
–
Part
2
Exploratory
•
PK:
RC220
and
doxorubicin
as
monotherapies
and
in
combination.
•
PD
biomarker:
DNA
double-strand
breaks
(γ-H2AX)
as
a
surrogate
marker
for
Cardioprotection.
•
Patient-reported
outcomes
&
cardiac
outcomes:
Quality
of
life
and
alopecia
(EORTC
QLQ-C30,
NCI-PRO-CTCAE)
and
incidence
of
CTRCD
per
2022
ESC
criteria.
•
Survival:
Overall
survival
(OS).
STUDY
OBJECTIVES
STUDY
DESIGN
This
is
an
open-label,
multicentre,
two-part
Phase
1
BOIN
design
study
evaluating
RC220
in
combination
with
doxorubicin
(DOX)
in
patients
with
advanced
or
metastatic
solid
tumours.
KEY
INCLUSION
AND
EXCLUSION
CRITERIA
METHODS
INCLUSION
CRITERIA:
•
All
patients:
Age
18–80
years
(≥19
Korea);
ECOG
PS
0–1;
life
expectancy
≥3
months;
measurable/evaluable
disease;
adequate
organ
function;
informed
consent
and
protocol
compliance.
•
Part
1:
Locally
advanced/unresectable
or
metastatic
solid
tumour;
prior
treatment
failure;
anthracycline
indicated.
•
Part
2:
Solid
tumour,
any
stage;
anthracycline-naïve;
doxorubicin
indicated.
EXCLUSION
CRITERIA:
•
All
patients:
Recent
anticancer
therapy
or
unresolved
>Grade
2
AEs;
CNS
malignancy/symptomatic
CNS
disease;
immunosuppressive/myelosuppressive
therapy;
bleeding/thrombotic
disorders;
recent
CYP3A4/2D6
or
P-gp
modulators;
significant
cardiac
disease/arrhythmias.
•
Part
1:
≥20%
sustained
drop
in
serum
albumin
at
screening;
severe/uncontrolled
cardiac
disease
or
recent
MI;
prior
anthracycline
exceeding
max
lifetime
dose.
•
Part
2:
Severe/uncontrolled
cardiac
disease
precluding
doxorubicin
therapy.
Start
Dose:40mg/m
2
PART
2
SCHEMATIC:
Dose
Expansion
-
Safety
&
Preliminary
efficacy
at
the
MTCD
CYCLE
1
-
6
RC220
MTD
+
DOX
EOT/
12
m
FUP
Survival
Long
term
FUP
2
years
Solid
tumour
patients
ANT
naïve
that
may
benefit
from
doxorubicin
treatment
Study
Status
PART
1
SCHEMATIC:
Dose
Escalation
-
Safety
&
Determine
the
MTCD
SAFETY
LEAD-IN
RC220
*
DL1
–
5
SAFETY
LEAD-IN
DOX
*
CYCLE
1
RC220
DL+DOX
**
CYCLE
2
-
6
RC220
+
DOX
**
(same
dose
level)
END
OF
TREATMENT
12
m
FUP/
Surviva
l
MTCD
Declared
Safety
Review
Committee
Interim
Analysis
*
RC220
IV
on
Day
1
of
each
21-day
cycle
**
RC220
IV
followed
by
doxorubicin
IV
on
Day
1
of
each
21-day
cycle
PART
2
START
Advanced/metastatic
patients
with
potential
benefit
from
doxorubicin
treatment
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 3
About Racura Oncology
Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to
silence cancer.
Racura’s lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that
primarily acts by stabilising G4-DNA and RNA structures, driving potent silencing of c-MYC, a key cancer
gene dysregulated in up to 70% of all cancers. (E,E)-bisantrene has shown therapeutic activity in cancer
patients and has a well-characterised safety profile. Racura’s discoveries have supported composition-of-
matter IP filings that, if granted, could provide up to 20 years of patent protection for (E,E)-bisantrene.
Racura is advancing RC220, its proprietary formulation of (E,E)-bisantrene, to address significant unmet
need across multiple MYC-driven oncology indications. The Company’s clinical programs include the EMILI
Phase 3 trial in acute myeloid leukaemia, the HARNESS Phase 1a/b trial in combination with osimertinib
for EGFR-mutated non-small cell lung cancer, and the CPACS Phase 1a/b trial in combination with
doxorubicin, where Racura aims to deliver both anthracycline cardioprotection and enhanced anticancer
activity.
Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson Cancer Center,
Sheba Medical Center, University of North Carolina School of Medicine, University of Wollongong, and the
University of Newcastle. Racura is actively exploring partnerships, licence agreements, and potential
commercial merger and acquisition opportunities to accelerate global patient access to RC220.
Learn more at www.racuraoncology.com.
For questions about this announcement or previous Racura Oncology announcements, please visit our
Interactive Announcements page.
Racura encourages our investors to go paperless by registering their email details with the Company’s
share registry, Automic Registry Services, at www.automicgroup.com.au.
Release authorised by Media Contact
Daniel Tillett, CEO Cherie Hartley +61 418 737 020
info@racuraoncology.com cherie.hartley@irdepartment.com.au
Share your feedback
Discover